Allergy & Immunology Flashcards

1
Q

Asthma Pathophysiology

A

After an episode: airways fill w/ mucus,muscles around the airway contract, airways swell

Obstruction- partially reversible w/ bronchodilator therapy

Hyperresponsiveness- abnormal response to external stimuli

Chronic inflammation
mast cell activation → inflammatory cell infiltration: eosinophils, helper T-cells lymphocytes, neutrophils

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Asthma Predictive Index

A

Criteria utilized to predict a diagnosis of asthma for ages 3 or younger w/ 4 + wheezing episodes within the past year:

Major (need 1)
- Parent w/ asthma
- Diagnosis of eczema
- Sensitivity to aeroallergens
Minor (need 2)
- Food allergy
- >4% eosinophils in blood
- Wheezing not associated w/ URI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Asthma classification: symptoms

A

Intermittent: </= 2 days/week
Persistent: mild, moderate, severe
- Mild > 2 days/ week, but not daily
- Moderate- daily
- Severe- throughout the day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Asthma classification: severity

A

Impairment
- nighttime awakenings
- SABA use
- interference with normal activity
- lung function

Risk
-exacerbation requiring oral steroid use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Asthma classification: control

A

3 categories:
- Well controlled - little to no use of rescue inhaler
- Not well controlled- increasing use of rescue inhaler
- Very poorly controlled- excessively using rescue

Assessed as often as every 1-6 mts
Therapy adjustments made based on asthma classification + level of control

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Asthma Diagnostic Criteria

A

Current episodic symptoms of airflow obstruction
- Cough, wheezing, SOB, chest tightness
Airway flow obstruction or airflow limitations that is partially reversible with bronchodilator
- Younger children with positive clinical response to bronchodilator
- Older children with evidence of improvement measured by spirometry
Alternative diagnosis excluded

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Quick Relief Medications

A

SABA- albuterol MDI or nebulized

Oral corticosteroid- prednisone, methylprednisolone, dexamethasone

Anticholinergic- ipratropium bromide MDI or nebulized

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Short acting beta agonist (SABA)

A

quick relief
albuterol - metered dose inhaler (MDI) or nebulized

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Anticholinergic (asthma)

A

quick relief
ipratroprium bromide (MDI or nebulized)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Oral steroids (asthma)

A

quick relief
prednisone, prednisolone methylprednisolone (1-2 mg/kg/day; max 60mg/day)
dexamethasone (0.3-0.6 mg/kg/day; max 12-16 mg/day)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Long term controllers

A

Inhaled corticosteroid (ICS)- Budesonide, fluticasone, beclomethasone,mometasone
SABA+ICS
LABA- salmeterol, formoterol
LABA+ICD-Fluticasone+Salmeterol, Budesonide+Formoterol, Mometasone+Formoterol (dulera)
Leukotriene receptor antagnonists (LRA)- montelukast

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Inhaled corticostroids (ICS)

A

long term controller
Budesonide, fluticasone, beclomethasone, mometasone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

LABA

A

long term controller
salmeterol, formoterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

LABA + ICS

A

long term controller
Fluticasone+Salmeterol (advair, airduo)
Budesonide+Formoterol (symbicort)
Mometasone+Formoterol (dulera)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Leukotriene receptor antagonist (LRA)

A

long term controller
Montelukast

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Asthma differentials

A

Allergic rhinosinusitis
Sinusitis
Adenoid or tonsillar hypertrophy
Foreign body
Vocal cord dysfunction
Tracheobronchomalacia
Cystic fibrosis
Bronchiolitis
Pneumonia
Bronchiectasis
Gastroesophageal reflux
Adverse reaction to ACE inhibitor meds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Increased risk of asthma death

A

History of sudden, severe exacerbation
Prior ICU admission
Prior intubation for asthma
2 or > hospitalizations or > 3 ED visits
Using >1 canister of SABA in short period of time
Chronic oral steroid use
Inability / difficulty perceiving severity of asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Status Asthmaticus

A

Severe asthma exacerbation

Risks include:
-multiple hospitalizations
-prior intubation
-prior attack with severe, unexpected & rapid deterioration
-frequent beta agonist use
-abrupt cessation of ICS

Manifestations:
coughing, wheezing, difficulty breathing, retractions, complaint of chest pain, nasal flaring, grunting, head bobbing, difficulty speaking in sentences, anxious

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Signs of impending respiratory failure

A

Altered mental status
Cyanosis
Decreased breath sounds
Difficult to speak more than a few words in a single breath

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Status asthmaticus PE/management

A

PE: tachycardia, tachypnea, pulsus paradoxus (decrease in SBP of >10 mmHg during inspiratory phase), hypoxemia

Observe LOC, hydration status, peripheral perfusion (check cap refill)

Management - hospitilization
Oxygen if hypoxic
IVF for rehydration
Bronchodilator therapy, anticholinergics, magnesium sulfate IV
IV corticosteroid - Methylprednisolone 2-4mg/kg/day given every 6-12 hrs (max 60 mg/day)
PICU if requires positive pressure ventilation (PPV), sedation or IV bronchodilator infusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Asthma Control Test (ACT)

A

Score of 19 or less - asthma may not be controlled

22
Q

Asthma Action Plan

A

Green zone- doing well
Yellow zone-
- cough, wheeze, chest tightness, or SOB or
- Waking at night d/t asthma or
- Can do some, but not all, usual activities
- Add on quick relief, If not in green zone after 1 hr of treatment, add something else
Red zone
- Very short of breath, or
- Quick relief medicines have not helped
- Cannot do usual activities
- Symptoms are same or get worse after 24 hrs in yellow zone

23
Q

Allergic Rhinitis

A

Exposure to allergen → IgE production →binds to mast cells of upper airway

Allergen exposure triggers release of:
- histamines (rhinorrhea, congestion, sneezing)
- leukotrienes
- prostaglandins
- cytokines (eosinophilic reaction- edema)

Common triggers: dust mites, roaches, pollen, animals, molds

Clinical manifestations: runny nose, sneeze, itchy eyes, headache

24
Allergic Rhinitis exam features/sequelae/diagnostics
**Exam features:** nasal crease, allergic shiners, allergic salute **Concerning sequelae**: Chronic OME; frequent AOM Sinusitis Nasal speech Mouth breathing secondary to enlarged tonsils and adenoids; high arched palate, malocclusion Snoring, poor sleep Nasal polyps- rare in children except CF pts **Diagnostics:** Clinical diagnosis - usually need 1-2 seasons of exposure Serum labs can be normal in children w/ AR Cytology testing of nasal secretions is available, not routinely done in primary care Skin testing or serum IgE testing can identify environmental factors to help guide mitigation strategies
25
AR treatment guidelines
**Environmental control ** Frequent laundering of bed linen, limiting stuffed animals & pets in the bedroom; pest control Utilize air filters, dehumidifiers to combat mold **Avoidance of triggers when possible** Less outdoor play during high pollen times Immediate removal of clothing and showering after outdoor exposures **Pharmacologic** - Antihistamines- cetirizine, loratadine, fexofenadine - Nasal steroids (pt should fully evacuate nose prior to use)- Fluticasone propionate (4 yrs+), mometasone, triamcinolone (2 yrs +) - Leukotriene receptor antagonist- montelukast - Decongestants- short term use, ensure age appropriate dosing Long term use can lead to rebound congestion, can cause hyperactivity and irritability in children Not recommended under 6 yrs If first line treatment fails or effects wane- referral may be necessary for skin testing
26
Atopic Dermatitis
IgE mediated type I & cell mediated type IV reaction → results in inflammatory changes in epidermis Mutation of filaggrin gene (FLG) → results in loss of function leading to entry of allergens and transepidermal water loss Triggers: airborne allergens, food, contact allergens, infectious agents
27
Atopic Dermatitis Diagnostic Criteria
(Criteria for diagnosis by Hanifin & Lobitz) Essential features: - Pruritus, eczematous dermatitis in age specific pattern - Chronic or relapsing Important features: - Early age at onset, atopy, xerosis Common associated features - Atypical vascular response; keratosis pilaris, ocular changes, lichenification
28
AD: age specific distribution
**Infants and toddlers** May appear as a rash on the scalp, face or arms and legs **Children** May begin inside creases of the elbow or knees, the neck, wrists, ankles, and/or the crease between the buttocks/legs **Adults** Often shows on the inner creases of the elbows or knees, hand, and/or nape of the neck
29
AD differentials/diagnostics
**Differentials**: Scabies Seborrheic dermatitis Psoriasis Histiocytosis X Severe combined immunodeficiency Acrodermatitis enteropathica **Diagnostics:** Not necessary for diagnosis, can be considered if there is coinciding asthma or allergic rhinitis and you want to identity triggers Refractory cases may require testing to identify underlying genetic conditions Skin culture if secondarily infected- impetigo, mrsa Biopsy rare but can be useful
30
AD treatment
**Dry skin** Moisturizers Emollients in either cream or ointment form Shortened bath times, use of mild soaps **Inflammation** Topical corticosteroids creams or ointments Nonsteroidal immunomodulators **Pruritus**- consider oral antihistamine- mixed data on effectiveness Hydroxyzine or diphenhydramine at bed time **Behavior modification** - rubbing instead of scratching, socks or mittens at bedtime, keep nails trimmed **Nonsteroidal options** (after first line of moisturization and second line of mild/medium potency steroid) Calcineurin inhibitors: Tacrolimus and Pimecrolimus Black box warning - increased risk of cancer associated with oral, topical has been found safe to date Safe to apply on body and face for mild-moderate AD Phosphodiesterase-4 (PDE-4) inhibitor- Crisaborole Anti inflammatory and anti-itch Burning or stinging common side effect **Home interventions** Wet wrap therapy- put on layer of lukewarm wet clothing, and put dry layer overtop Cut fingernails short Teach to pat/rub and not scratch Avoid food triggers once identified- hydrolyzed formula for infants w/ mild protein allergy Moisturize often Refer if: → Dermatology or allergist: No response to first or second line therapy If has HPV or Molluscum contagiosum involvement Severely infected may require hospitalization for IV abx: - Staphylococcus - Eczema herpeticum/ kaposi varicelliform eruption
31
AD topical corticostroid potencies
Low potency: Desonide 0.05% Hydrocortisone 0.5-2.5% Medium potency: Bethamethasone valerate 0.1% Triamcinolone acetate 0.1%, 0.5% Flurandrenolide 0.05% Flutcasone proprionate 0.05% High potency: Betamethasone diproprionate 0.05% Clobetasol proprionate 0.05% Halobetasol proprionate 0.05%, 0.25% Flucinonide 0.05% generally limit high potency TCS to < 2 weeks duration gel formulation are highest potency
32
Urticaria
Rash produced by capillary leak vasodilation & edea of skin Occurs as a result of histamines, prostaglandins, and leukotrienes being released from epidermal mast cells Triggers: IgE mechanisms, viral, bacterial, parasitic, and fungal infections, collagen vascular disease, malignancy, endocrine disease, and physical factors like heat, cold, pressure, sun, vibration Erythematous, popular, coalesce, blanching, last <24 hrs but can recur, itchy
33
Angioedema
Extension of uritcarial process deeper into the dermis +/- mucous membrane involvement tissue swelling, tightness involvement of abdominal viscera results in colicky abdominal pain
34
Urticaria & Angioedema management
Eliminate offending agent Manage underlying infections Manage underlying condition Medications - Antihistamines 1st (diphenhydramine) and 2nd gen (claritin, zyrtec, allegra) - H2 receptor antagonists- cimetidine, famotidine, ranitidine (helpful for GI manifestations) - systemic steroids (for angioedema)
35
Food Allergies
most common: milk, egg, wheat, soy - resolve in childhood peanut, tree nut, shellfish, fish- can resolve, but more likely to be persistent Clinical manifestations: suspect when the following are present within minutes or hours after food ingestion- - Urticaria - Edema - Wheezing - Mouth itch- children may not verbalize but will rub tongue against top of mouth, or click with tongue - Cough - Nausea / vomiting - Anaphylaxis
36
Food allergy diagnosis
- based on history & clinical presentation - medically managed food challenge is the most definitive test for food allergy - food specific IgE testing (should not be sole source used for diagnosis) In children w/ **moderate** to **severe eczema** that are **< 5 yrs**, food allergy should be considered for **milk, wheat, peanut, egg, and soy** if at least 1 of the following are met - The child has persistent AD in spite of optimized management and topical therapy - The child has a reliable history of an immediate reaction after ingestion of a specific food
37
Prevention of peanut allergy
Infant w/ severe eczema, egg allergy, or both- consider eval by IgE and/or skin prick test (SPT), if necessary OFC, based on results, introduce peanu containing food (4-6mts) Infant w/ mild to moderate eczema- introduce peanut containing food (6 mts) Infant w/ no eczema or food allergy- introduce peanut containing food at any age appropriate time
38
Anaphylaxis
Multisystem reaction that occurs suddenly after contact w/ a substance/mechanism Constellation of symptoms involving multiple organ systems: **Skin (90% of cases)**- flushing, pruritus, urticaria, angioedema **GI (30% of cases)**- nausea, abdominal pain (colic), vomiting (large amounts of “stringy” mucus), and diarrhea **Respiratory (70% of cases; most common cause of death in children)** - laryngeal: pruritus and “tightness” in the throat, dysphagia, dysphonia and hoarseness, dry “staccato” cough. - Lung: dyspnea, chest tightness, “deep” cough, and wheezing; - nose- pruritus, congestion, rhinorrhea, and sneezing **CV (20% of cases)**- feeling of faintness, syncope, chest pain, dysrhythmia, hypotension, shock
39
Anaphylaxis diagnostic criteria
Highly likely when 1 of the following 3 criteria are met **Criterion 1**: acute onset (minutes to several hours) with *involvement of skin, mucosal tissue*, or both, *even in the absence of known or suspected trigger* and at least* one* of the following: - Respiratory compromise - Reduced BP or associated symptoms of end-organ dysfunction (collapse, syncope, incontinence) **Criterion 2**:* two or more *of the following occur rapidly (minutes to several hours) after *exposure to a likely allergen* - Involvement of the skin or mucosal tissue - Respiratory compromise - Reduced BP or associated end-organ dysfunction - Persistent GI symptoms **Criterion 3**: reduced BP rapidly (minutes to several hours) after exposure to known allergen
40
Anaphylaxis categories
Uniphasic - anaphylactic reaction, treated, and pt improves Biphasic (up to 14% of cases) Develop initial symptoms Appear to recover Develop symptoms again Protracted- lasts 1 day-3 weeks
41
Anaphylaxis management/ discharge
1. Assess airway, breathing, circulation, and neuro status - continue to monitor throughout 2. Place in recumbent position 3. Administer Epinephrine IM - do not wait for symptoms development -administer at onset of mild symptoms (pruritus, urticaria, etc.) - may use epipen or epi vial Child - **0.1mg/kg/dose IM/SC** up to max of 0.5mg/dose q20 min- 4 hrs prn Adult - **0.1-0.5 mg IM/SC** q20min-4 hr prn; may increase to single max dose of 1 mg 4. Administer supplemental O2 in patients w/ respiratory symptoms 5. Bolus of NS (20-40 ml/kg) in patients w/ hypotension Second line therapies: - antihistamine (diphenhydramine 1-2mg/kg) - steroid (oral prednisone or IV methylprednisolone at 1-2 mg/kg/dose) - inhaled SABA for wheezing **Discharge**: Mild anaphylaxis- 4-6 hrs observation Moderate anaphylaxis- 6-8 hrs observation Severe anaphylaxis- admit for at least 24 hrs obs Diagnostics for unknown cause Trigger avoidance education Auto injector epinephrine (AIE) prescription for 2 autoinjectors - **<30kg: 0.15 mg (epipen junior)** -** >/=30kg: 0.3 mg** Educate to seek immediate medical attention anytime anaphylaxis occurs Written emergency plan
42
Erythema Multiforme
Cutaneous and mucosal hypersensitivity reaction w/ characteristic lesions triggered by a stimuli Lesions appear on the skin favoring the extremities and usually resolve within 7-21 days Mucous membranes are involved in about 10% of cases Etiology: HSV (likely to re occur in pts), mycoplasma pneumoniae, other virsues, bacteria, fungi, drugs, heavy metals, herbals, topical therapies, poison ivy Increased risk: HIV, corticostroid therapy, immunosuppresion, BMT recipient, Lupus
43
Erythema Multiforme Minor
Typical skin lesions w/ symmetrical acral (peripheral) distribution (limbs) Mucous membrane involvement is rare, only single mucosa, usually mouth Healing takes 2-3 weeks
44
Erythema Multiforme Major
Skin lesions are extensive but less than 10% of body surface area Typical target lesions present Mucosal involvement is severe and affects at least 2 mucosal sites Healing takes 4-6 weeks
45
Erythema Multiforme clinical presentation
Fever and feeling of unease prior to or accompanying the eruption Arthralgia, joint swelling Target lesion is typical- symmetrical, trunk is usually spared, some complain of burning sensation but no itching Mucosal lesions are most common in the mouth - Bullous then painful erosion - May note white coating Pulmonary system may be involved with cough, dyspnea (particularly w/ mycoplasma pna if that is trigger)
46
Multiforme Erythema differentials/ diagnostics
**Differentials:** Pityriasis rosea Urticaria Viral exanthems Stevens johnson syndrome Hypersensitivity reaction **Diagnostics:** Diagnosis is clinical Skin biopsy of lesion center Look for current HSV outbreak (oral and genital or other parts of the body) Consider CXR with cough, respiratory symptoms (M. pneumoniae) CBC/D - Mild leukocytosis - Neutropenia - Mild anemia Chemistry if concern for dehydration (d/t mouth lesions)
47
Multiforme Erythema treatment
Topical treatment -antiseptics for bullous lesions - antiseptic mouthwash - anesthetic - topical steroid Ocular involvement- refer to ophtha M. Pneumoniae- azitrhomycin HSV- acyclovir Hospitalize for - dehydration - pain control - extensive lesions w/ burn like qualities- to decrease likelihood of secondary infection
48
Stevens-Johnson Syndrome (SJS)
Rare, acute, serious and potentially fatal skin reaction Characterized by sheet-like skin and mucosal loss accompanied by systemic symptoms Medications are the cause in over 80% of cases: anticonvulsants, allopurinol, sulfonamides, antibiotics, APAP, nevirapine, NSAIDs, contrast media
49
SJS Clinical Manifestations
Begins w/ nonspecific symptoms like fever, malaise, URI symptoms Blistering rash and erosions appear to the face, trunk, limbs, and mucosal surfaces - erythematous, target like, annular, or purpuric macules - bullae - large painful erosions - Nikolsky positive- lateral pressure on the skin results in shedding of the epidermis Mucosal ulcerations involving the lips, mouth, pharynx, esophagus, GI tract, eyes, genitals, upper respiratory tract Patient is ill appearing and in pain Liver, kidneys, lungs, bone marrow, joints may be involved
50
SJS management/prognosis
**Treatment/ management:** Hospitalization- preferably burn care unit Cessation of causative drug Fluid replacement Nutritional support Temp control, pain control Supplemental O2 and ven support if needed Skin care Abx to treat secondary infections **Prognosis:** at risk for secondary infections & organ failure more common complicationsL blindness, scarring, renal scarring mortality up to 20%
51
IgA Vasculitis
IgA collects in small blood vessels → becomes inflamed & leaks blood Most common vasculitis in children (<10 yrs, males> females) Clinical findings: - may be proceeded by URI (likely trigger) - skin rash (palpable purpura to buttocks and LE) - arthritis (60-80%) - colicky abdominal pain (50-70%), may proceed rash - renal involvement (20-60%)
52
IgA diagnostic criteria
based on clinical presentation 2 or more of the following: -palpable purpura (usually to the LEs) -initial presentation at 20 yrs or younger -bowel angina (manifests as colicky abdominal pain) -typical renal biopsy findings
53
IgA diagnostics/management
Diagnostics: UA and BP- monitor for renal involvement (baseline, then q month x 6 mts) Consider Stool guaiac for occult blood Abdominal CT (if obstruction suspected) Renal biopsy if -proteinuria > 1 mt -renal insufficiency -HTN -nephrotic syndrome Management -symptomatic , analgesics for mild joint pain - monitor for hematuria & proteinuria - monitor BP - refer/consult for GI, renal, significiant joint involvement usually runs its course within 3-4 wks, rash may recur for up to 1 yr